Doctor of Optometry Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Alden Negaard

Optometrist Bellaire, TX Doctor of Optometry

NPI 1952984429 CMS profile 8803275

6565 West Loop S Ste 650, Bellaire, TX 77401

Open in the dashboard

General payments

$7,005

183 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alden Negaard of Bellaire, TX is reported in the CMS Open Payments database as having received $7,005 across 183 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,905 52
2024 General $1,746 43
2023 General $1,683 47
2022 General $968 21
2021 General $658 18
2020 General $46 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alden Negaard
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Alden Negaard were reported at $1,905. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Alden Negaard Optometrist median Middle half National median
2019 $0 $159 $67–$371 $163
2020 $46 $72 $29–$165 $114
2021 $658 $125 $46–$292 $132
2022 $968 $162 $66–$374 $149
2023 $1,683 $177 $72–$406 $160
2024 $1,746 $188 $77–$427 $164
2025 $1,905 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Sun Pharmaceutical Industries Inc. $1,005 19 payments
  2. Tarsus Pharmaceuticals, Inc. $770 28 payments
  3. Oyster Point Pharma, Inc. $717 22 payments
  4. Bausch & Lomb Americas Inc. $631 22 payments
  5. Harrow Eye, LLC $582 8 payments
  6. AbbVie, Inc. $515 12 payments
  7. Allergan Inc. $437 4 payments
  8. Alcon Vision LLC $421 14 payments
  9. Glaukos Corporation $364 3 payments
  10. TissueTech, Inc. $362 6 payments
  11. Other $1,200 45 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $6,979 182 payments
  2. Travel and Lodging $26 1 payment
Products named General payments · program years 2020–2025
  1. Cequa $1,005 19 payments
  2. XDEMVY $770 28 payments
  3. TYRVAYA $548 15 payments
  4. XIIDRA $369 25 payments
  5. VUITY $312 3 payments
  6. DURYSTA $299 5 payments
  7. Rocklatan $296 8 payments
  8. PROKERA $275 2 payments
  9. AMNIOGRAFT $275 2 payments
  10. VEVYE $265 6 payments
  11. Other $3,783 120 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 35 drugs

Part D claims

2,781

Median for Optometry: 120

Drug cost

$1,117,648

Median for Optometry: $8,864

Branded share of claims

47.8%

Median for Optometry: 24.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxervate Cenegermin-Bkbj Brand 14 $394,910
Xdemvy Lotilaner Brand 68 $128,433
Xiidra Lifitegrast Brand 89 $120,236
Restasis Cyclosporine Brand 86 $112,065
Lumigan Bimatoprost Brand 145 $74,738
Tyrvaya Varenicline Tartrate Brand 64 $52,331
Rhopressa Netarsudil Mesylate Brand 84 $46,119
Vyzulta Latanoprostene Bunod Brand 61 $35,861
Combigan Brimonidine Tartrate/Timolol Brand 54 $24,551
Vevye Cyclosporine Brand 21 $17,244

The 10 drugs with the highest cost, of 35 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 27,653 Part D prescribers listed as Optometry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 24 billing codes

Paid by Medicare

$161,563

Medicare's payments for the services billed

Medicare patients

856

Average age 76

Services billed

2,615

539 women, 317 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Diabetes 35%
Ischemic heart disease 32%
Chronic kidney disease 23%
Atrial fibrillation 18%
Cancer 17%
Heart failure 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XDEMVY
  • Tarsus Pharmaceuticals, Inc. $266
$266 68 —
MIEBO
  • Bausch & Lomb Americas Inc. $115
$115 19 —
OXERVATE
  • Dompe US, Inc. $111
$111 14 —
Rocklatan
  • Alcon Vision LLC $110
$110 30 —
Cequa
  • Sun Pharmaceutical Industries Inc. $94
$94 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

183 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record